Zonisamide

Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. (In Vitro) :Zonisamide (10, 50, 100, 200 μM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect.Zonisamide (100 μM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease) .Zonisamide (100 μM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis) .Zonisamide (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro.Zonisamide markedly increases the expression of Hrd1 in Ang II-treated NRCMs. (In Vivo) :Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction) .Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.

68291-97-4

CI-912 | PD 110843

Pharmacology & Drug Discovery

>98% (HPLC)

Ethanol: 5 mg/mL (23.55 mM) ; DMSO: 42 mg/mL (197.89 mM)

O=S (CC1=NOC2=CC=CC=C12) (N) =O

C8H8N2O3S

212.23

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.